Depomed (DEPO) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
DepoMed (DEPO) PT Bumped to $19 at Piper Jaffray, Remains Sidelined
August 4, 2016 7:29 AM EDTPiper Jaffray analyst David Amsellem bumped his price target on DepoMed Inc (NASDAQ: DEPO) to $19.00 (from $18.00) but maintained a Neutral rating.
Amsellem commented, "Depomed reported 2Q16 diluted EPS of $0.27 on revenue of $117M, compared to Street estimates of $0.25 and $118M, respectively. Notably, DEPO... More
